Year
DEALS // DEV.
Country
Therapeutic Area
Study Phase
Deal Type
Product Type
Dosage Form
Lead Product
Target
Lead Product(s) : Dupilumab
Therapeutic Area : Gastroenterology
Study Phase : Phase III
Sponsor : Regeneron Pharmaceuticals
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : Dupixent (dupilumab), a fully human monoclonal antibody that inhibits the signaling of the IL-4 and IL-13 pathways, shows positive results from a Phase 3 trial in children aged 1 to 11 years with eosinophilic esophagitis (EoE).
Product Name : Dupixent
Product Type : Antibody
Upfront Cash : Inapplicable
October 23, 2023
Lead Product(s) : Dupilumab
Therapeutic Area : Gastroenterology
Highest Development Status : Phase III
Sponsor : Regeneron Pharmaceuticals
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Dupilumab
Therapeutic Area : Gastroenterology
Study Phase : Phase III
Sponsor : Regeneron Pharmaceuticals
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : First and only investigational Phase 3 trial to show positive results in these young children; results follow recent approval of Dupixent (Dupilumab) in people with eosinophilic esophagitis aged 12 years and older who weigh at least 40 kilograms.
Product Name : Dupixent
Product Type : Antibody
Upfront Cash : Inapplicable
July 14, 2022
Lead Product(s) : Dupilumab
Therapeutic Area : Gastroenterology
Highest Development Status : Phase III
Sponsor : Regeneron Pharmaceuticals
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Dupilumab
Therapeutic Area : Gastroenterology
Study Phase : Phase III
Sponsor : Regeneron Pharmaceuticals
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : Dupixent 300 mg weekly, a fully human mAB that inhibits signaling of interleukin-4 and interleukin-13 pathways, significantly improved signs and symptoms of EoE at 24 weeks compared to placebo, including ability to swallow and reduction in eosinophil cou...
Product Name : Dupixent
Product Type : Antibody
Upfront Cash : Inapplicable
April 04, 2022
Lead Product(s) : Dupilumab
Therapeutic Area : Gastroenterology
Highest Development Status : Phase III
Sponsor : Regeneron Pharmaceuticals
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Dupilumab
Therapeutic Area : Gastroenterology
Study Phase : Phase III
Sponsor : Regeneron Pharmaceuticals
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : Dupixent is a fully human monoclonal antibody that inhibits the signaling of the interleukin-4 and interleukin-13. IL-4 and IL-13 are key drivers of the type 2 inflammation that plays a major role in atopic dermatitis, asthma and chronic rhinosinusitis w...
Product Name : Dupixent
Product Type : Antibody
Upfront Cash : Inapplicable
October 25, 2021
Lead Product(s) : Dupilumab
Therapeutic Area : Gastroenterology
Highest Development Status : Phase III
Sponsor : Regeneron Pharmaceuticals
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Dupilumab
Therapeutic Area : Gastroenterology
Study Phase : Phase III
Sponsor : Regeneron Pharmaceuticals
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : Dupixent’s unique mechanism of action simultaneously inhibits IL-4 and IL-13. Recent evidence further supports additional clinical uses in diseases driven by type 2 inflammation including Eosinophilic Esophagitis and a subset of Chronic Obstructive Pul...
Product Name : Dupixent
Product Type : Antibody
Upfront Cash : Inapplicable
November 06, 2020
Lead Product(s) : Dupilumab
Therapeutic Area : Gastroenterology
Highest Development Status : Phase III
Sponsor : Regeneron Pharmaceuticals
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Dupilumab
Therapeutic Area : Gastroenterology
Study Phase : Phase III
Sponsor : Regeneron Pharmaceuticals
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : First Phase 3 trial in eosinophilic esophagitis (EoE) to show a biologic medicine significantly improved structural and histologic measures, while rapidly improving ability to swallow in patients 12 years and older.
Product Name : Dupixent
Product Type : Antibody
Upfront Cash : Inapplicable
October 26, 2020
Lead Product(s) : Dupilumab
Therapeutic Area : Gastroenterology
Highest Development Status : Phase III
Sponsor : Regeneron Pharmaceuticals
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Dupilumab
Therapeutic Area : Gastroenterology
Study Phase : Phase III
Sponsor : Regeneron Pharmaceuticals
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : Dupixent is the first and only biologic to show positive and clinically-meaningful Phase 3 results in patients 12 years and older with eosinophilic esophagitis (EoE).
Product Name : Dupixent
Product Type : Antibody
Upfront Cash : Inapplicable
September 14, 2020
Lead Product(s) : Dupilumab
Therapeutic Area : Gastroenterology
Highest Development Status : Phase III
Sponsor : Regeneron Pharmaceuticals
Deal Size : Inapplicable
Deal Type : Inapplicable
Reset All
Sanofi is a pioneer in Diabetes Solutions, Human Vaccines, Innovative Drugs, Consumer Healthcare, and the new Genzyme.
